SCHEMBL4152514

SCHEMBL4152514

NC(=O)c1ccc(-c2ccccc2)c(-c2ccccc2)c1C(N)=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCAT2 O15382 2/20 0.56
MAP2 P11137 2/20 0.42
IKBKB O14920 4/20 0.42
CHUK O15111 2/20 0.41
IKBKE Q14164 1/20 0.41
PKMYT1 Q99640 1/20 0.41
HNF4A P41235 1/20 0.41
KDM4E B2RXH2 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
BRD4 O60885 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
KEAP1 Q14145 1/20 0.39
NFE2L2 Q16236 1/20 0.39
MAPT P10636 2/20 0.38
TSHR P16473 2/20 0.38
HSD17B10 Q99714 2/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4143761 0.86 BCAT2 (0.56) BCAT2MAP2IKBKBCHUKIKBKE
SCHEMBL4881197 0.85 BCAT2 (0.60) BCAT2IKBKBCHUKIKBKEPKMYT1
SCHEMBL28159776 0.85 BCAT2 (0.60) BCAT2MAP2IKBKBCHUKIKBKE
SCHEMBL8724979 0.84 BCAT2 (0.42) BCAT2IKBKBKEAP1NFE2L2PLA2G10
SCHEMBL28029850 0.84 BCAT2 (0.38) BCAT2IKBKBCHUKKDM4EMEN1
SCHEMBL27929339 0.83 CCNC (0.46) IKBKBCHUKIKBKEPKMYT1CASP1
SCHEMBL28278839 0.83 BTK (0.44) BCAT2KMT2AMAPTTSHRHSD17B10
SCHEMBL27911586 0.81 BCAT2 (0.55) BCAT2MAP2IKBKBCHUKIKBKE
SCHEMBL27708585 0.80 BCAT2 (0.50) BCAT2MAP2IKBKBCHUKIKBKE
SCHEMBL28029528 0.79 MAP4K4 (0.43) BCAT2IKBKBBRD4MAPTPLA2G10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090131657-A1 PROCESS FOR ALKENYLATING CARBOXAMIDES BASF SE (DE) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131657-A1 PROCESS FOR ALKENYLATING CARBOXAMIDES PRMT5, CYC1, CBR3 BCAT2 1188/4885MAP2 1310/4885IKBKB 3501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.